![black male scientist with mask](/sites/default/files/styles/445x610/public/media/images/black_male_scientist_with_mask.jpg.webp?itok=ZN3TrmCP)
PTCH1 biomarker and colorectal cancer
![black male scientist with mask](/sites/default/files/styles/445x610/public/media/images/black_male_scientist_with_mask.jpg.webp?itok=ZN3TrmCP)
![blue question mark](/sites/default/files/styles/fifty_fifty/public/media/images/blue_question_mark.jpg.webp?itok=tGDxm8NQ)
What is the PTCH1 biomarker?
The PTCH1 gene is a tumor suppressor gene that contains the instructions for making the patched-1 protein. The gene encodes a member of the patched family of proteins and is a component of the hedgehog signaling pathway.
![DNA strands in cloudy atmosphere](/sites/default/files/styles/fifty_fifty/public/media/images/dna_strands.jpg.webp?itok=aLTMO3J3)
How common is the PTCH1 mutation?
PTCH1 is altered in approximately 4 percent of colorectal cancer patients.
Some mutations are acquired during a person's lifetime and are present only in certain cells. These genetic changes, called somatic mutations, are not inherited.
![black woman receiving medicine from black female pharmacist](/sites/default/files/styles/fifty_fifty/public/media/images/black_woman_pharmacist_black_patient.jpg.webp?itok=hRaQpiPH)
What happens if I have the PTCH1 mutation?
Although there are no FDA approved therapies targeting PTCH1 mutations to date, there is a clinical trial investigating the efficacy of a potential treatment in cancer patients with PTCH1 Loss of Function mutations.
Other biomarkers
TMB BiomarkerTop resources
![A sign at the BMS headquarters](/sites/default/files/styles/450x250/public/media/images/bms-sign-1920.png.webp?itok=qtRzhXHJ)
Krazati approved for previously treated KRASG12C colorectal cancer
The treatment option is for patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
![Christy Williams, a mom and colorectal cancer survivor, plays a table-top game with her family.](/sites/default/files/styles/450x250/public/media/images/christy-3.png.webp?itok=DxDhUqH-)
Christy Williams: Biomarker testing leads to successful treatment
Statistics suggested that Christy’s odds of survival were grim, so she leaned into her faith and kept a positive outlook. She tried to control what she could. And, critically, she received biomarker testing.
![Michelle Cappel: Biomarker testing extends life](/sites/default/files/styles/450x250/public/media/images/article/michelle-c-web.png.webp?itok=fV1oBKbJ)
Michelle Cappel: Biomarker testing extends life
Michelle Cappel owes a lot to colorectal cancer biomarker testing — seven years of life and counting.